Phospho-MEK1 (Ser298) Antibody - #AF7346
| 製品: | Phospho-MEK1 (Ser298) Antibody |
| カタログ: | AF7346 |
| タンパク質の説明: | Rabbit polyclonal antibody to Phospho-MEK1 (Ser298) |
| アプリケーション: | WB IHC |
| 反応性: | Human, Mouse, Rat |
| 予測: | Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus |
| 分子量: | 45kDa; 43kD(Calculated). |
| ユニプロット: | Q02750 |
| RRID: | AB_2843786 |
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
引用形式: Affinity Biosciences Cat# AF7346, RRID:AB_2843786.
折りたたみ／展開
Dual specificity mitogen activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1; MAP kinase kinase 1; MAP kinase/Erk kinase 1; MAP2K1; MAPK/ERK kinase 1; MAPKK 1; MAPKK1; MEK 1; Mek1; MEKK1; Mitogen activated protein kinase kinase 1; MKK 1; MKK1; MP2K1_HUMAN; PRKMK1; Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1); Protein kinase mitogen activated, kinase 1;
免疫原
- Q02750 MP2K1_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV
種類予測
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - Q02750 基板として
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| T23 | Phosphorylation | Uniprot | |
| S24 | Phosphorylation | Q6VAB6 (KSR2) | Uniprot |
| S25 | Phosphorylation | Uniprot | |
| K36 | Ubiquitination | Uniprot | |
| T55 | Phosphorylation | O14757 (CHEK1) | Uniprot |
| K57 | Ubiquitination | Uniprot | |
| K64 | Ubiquitination | Uniprot | |
| K70 | Ubiquitination | Uniprot | |
| S72 | Phosphorylation | Q6VAB6 (KSR2) | Uniprot |
| K88 | Ubiquitination | Uniprot | |
| K97 | Ubiquitination | Uniprot | |
| K104 | Sumoylation | Uniprot | |
| K104 | Ubiquitination | Uniprot | |
| K168 | Ubiquitination | Uniprot | |
| K175 | Acetylation | Uniprot | |
| K175 | Ubiquitination | Uniprot | |
| K192 | Ubiquitination | Uniprot | |
| S194 | Phosphorylation | Uniprot | |
| K205 | Ubiquitination | Uniprot | |
| S212 | Phosphorylation | Uniprot | |
| S218 | Phosphorylation | P53350 (PLK1) , O15530 (PDPK1) , P15056 (BRAF) , P41279 (MAP3K8) , Q5TCX8 (MAP3K21) , P00540 (MOS) , Q13233 (MAP3K1) , P10398 (ARAF) , P04049 (RAF1) | Uniprot |
| S222 | Phosphorylation | Q5TCX8 (MAP3K21) , P10398 (ARAF) , Q13233 (MAP3K1) , P53350 (PLK1) , O15530 (PDPK1) , P00540 (MOS) , P04049 (RAF1) , P15056 (BRAF) , P41279 (MAP3K8) | Uniprot |
| T226 | Phosphorylation | Uniprot | |
| S231 | Phosphorylation | Uniprot | |
| S244 | Phosphorylation | P41279 (MAP3K8) | Uniprot |
| S248 | Phosphorylation | P41279 (MAP3K8) | Uniprot |
| T286 | Phosphorylation | Q00535 (CDK5) , P06493 (CDK1) , P27361 (MAPK3) , P28482 (MAPK1) | Uniprot |
| T292 | Phosphorylation | P06493 (CDK1) , P27361 (MAPK3) , Q00535 (CDK5) , P28482 (MAPK1) | Uniprot |
| S298 | Phosphorylation | Q13153 (PAK1) , Q02750 (MAP2K1) , O75914 (PAK3) | Uniprot |
| S299 | Phosphorylation | Uniprot | |
| Y300 | Phosphorylation | Q02750 (MAP2K1) | Uniprot |
| K344 | Ubiquitination | Uniprot | |
| K353 | Ubiquitination | Uniprot | |
| K362 | Acetylation | Uniprot | |
| S385 | Phosphorylation | Uniprot | |
| T386 | Phosphorylation | P28482 (MAPK1) , P27361 (MAPK3) | Uniprot |
| T388 | Phosphorylation | Uniprot |
PTMs - Q02750 酵素として
| Substrate | Site | Source |
|---|---|---|
| O75676-1 (RPS6KA4) | S196 | Uniprot |
| O75676-1 (RPS6KA4) | S343 | Uniprot |
| O75676-1 (RPS6KA4) | S347 | Uniprot |
| O75676-1 (RPS6KA4) | S360 | Uniprot |
| O75676-2 (RPS6KA4) | T562 | Uniprot |
| O75676-1 (RPS6KA4) | T568 | Uniprot |
| P04049 (RAF1) | S338 | Uniprot |
| P05787 (KRT8) | S74 | Uniprot |
| P15172 (MYOD1) | Y156 | Uniprot |
| P17542 (TAL1) | S122 | Uniprot |
| P27361 (MAPK3) | T202 | Uniprot |
| P27361 (MAPK3) | Y204 | Uniprot |
| P27361 (MAPK3) | T207 | Uniprot |
| P27361 (MAPK3) | Y210 | Uniprot |
| P28482 (MAPK1) | T185 | Uniprot |
| P28482 (MAPK1) | Y187 | Uniprot |
| P32121 (ARRB2) | T382 | Uniprot |
| P35568 (IRS1) | S307 | Uniprot |
| P37231 (PPARG) | S112 | Uniprot |
| P49841 (GSK3B) | Y216 | Uniprot |
| P55211-1 (CASP9) | T125 | Uniprot |
| Q00613 (HSF1) | S326 | Uniprot |
| Q02750 (MAP2K1) | S298 | Uniprot |
| Q02750 (MAP2K1) | Y300 | Uniprot |
| Q02750-1 (MAP2K1) | S304 | Uniprot |
研究背景
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase kinases (BRAF or MEKK1) positively regulates kinase activity. Also phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK. MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to cellular adhesion and leads to inhibition of Ser-298 phosphorylation by PAK.
Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
Cytoplasm>Cytoskeleton>Microtubule organizing center>Centrosome. Cytoplasm>Cytoskeleton>Microtubule organizing center>Spindle pole body. Cytoplasm. Nucleus. Membrane>Peripheral membrane protein.
Note: Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis (PubMed:14737111). Membrane localization is probably regulated by its interaction with KSR1 (PubMed:10409742).
Widely expressed, with extremely low levels in brain.
Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3/ERK1 and RGS14 (By similarity). Forms a heterodimer with MAP2K2/MEK2 (By similarity). Forms heterodimers with KSR2 which further dimerize to form tetramers (By similarity). Interacts with KSR1 or KSR2 and BRAF; the interaction with KSR1 or KSR2 mediates KSR1-BRAF or KSR2-BRAF dimerization. Interacts with ARBB2, LAMTOR3, MAPK1/ERK2 and RAF1 (By similarity). Interacts with MORG1 (By similarity). Interacts with PPARG. Interacts with isoform 1 of VRK2. Interacts with SGK1. Interacts with BIRC6/bruce. Interacts with KAT7; the interaction promotes KAT7 phosphorylation (By similarity).
(Microbial infection) Interacts with Yersinia yopJ.
The proline-rich region localized between residues 270 and 307 is important for binding to RAF1 and activation of MAP2K1/MEK1.
Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
研究領域
· Cellular Processes > Cell growth and death > Oocyte meiosis. (View pathway)
· Cellular Processes > Transport and catabolism > Autophagy - animal. (View pathway)
· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)
· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)
· Cellular Processes > Cellular community - eukaryotes > Focal adhesion. (View pathway)
· Cellular Processes > Cellular community - eukaryotes > Gap junction. (View pathway)
· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells. (View pathway)
· Cellular Processes > Cell motility > Regulation of actin cytoskeleton. (View pathway)
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Rap1 signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > mTOR signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Apelin signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)
· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.
· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.
· Human Diseases > Neurodegenerative diseases > Prion diseases.
· Human Diseases > Substance dependence > Alcoholism.
· Human Diseases > Infectious diseases: Viral > Hepatitis B.
· Human Diseases > Infectious diseases: Viral > Influenza A.
· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Proteoglycans in cancer.
· Human Diseases > Cancers: Overview > MicroRNAs in cancer.
· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Renal cell carcinoma. (View pathway)
· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Glioma. (View pathway)
· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Thyroid cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)
· Human Diseases > Cancers: Specific types > Bladder cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)
· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)
· Human Diseases > Cancers: Specific types > Non-small cell lung cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)
· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)
· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Choline metabolism in cancer. (View pathway)
· Organismal Systems > Immune system > Chemokine signaling pathway. (View pathway)
· Organismal Systems > Circulatory system > Vascular smooth muscle contraction. (View pathway)
· Organismal Systems > Development > Osteoclast differentiation. (View pathway)
· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)
· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)
· Organismal Systems > Immune system > T cell receptor signaling pathway. (View pathway)
· Organismal Systems > Immune system > B cell receptor signaling pathway. (View pathway)
· Organismal Systems > Immune system > Fc epsilon RI signaling pathway. (View pathway)
· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis. (View pathway)
· Organismal Systems > Nervous system > Long-term potentiation.
· Organismal Systems > Nervous system > Neurotrophin signaling pathway. (View pathway)
· Organismal Systems > Nervous system > Cholinergic synapse.
· Organismal Systems > Nervous system > Serotonergic synapse.
· Organismal Systems > Nervous system > Long-term depression.
· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)
· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.
· Organismal Systems > Endocrine system > Estrogen signaling pathway. (View pathway)
· Organismal Systems > Endocrine system > Melanogenesis.
· Organismal Systems > Endocrine system > Prolactin signaling pathway. (View pathway)
· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)
· Organismal Systems > Endocrine system > Oxytocin signaling pathway.
· Organismal Systems > Endocrine system > Relaxin signaling pathway.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.